Literature DB >> 17392160

Activation of caspase-6 in aging and mild cognitive impairment.

Steffen Albrecht1, Martine Bourdeau, David Bennett, Elliott J Mufson, Meena Bhattacharjee, Andréa C LeBlanc.   

Abstract

Active caspase-6 (Csp6) and Tau cleaved by Csp6 (TauDeltaCsp6) are abundant in neuritic plaques (NPs), neuropil threads (NPTs), and neurofibrillary tangles (NFTs) in end-stage Alzheimer's disease (AD) (Guo H, Albrecht S, Bourdeau M, Petzke T, Bergeron C, LeBlanc AC: Active caspase-6 and caspase-6 cleaved Tau in neuropil threads, neuritic plaques and neurofibrillary tangles of Alzheimer's disease. Am J Pathol 2004, 165:523-531). The goal of this study was to determine whether active Csp6 is present in young and aged noncognitively impaired (NCI); aged mild cognitively impaired (MCI); and aged mild, moderate, severe, and very severe AD individuals. Csp6 activity was assessed with anti-p20Csp6 and TauDeltaCsp6 immunoreactivity. Active Csp6 is present in NFTs, NPTs, and NPs at all stages of AD. Active Csp6 is present in NFTs of all MCI cases and present in NPTs and NPs of some MCI cases. Active Csp6 is present in NFTs and NPTs of all NCI cases but is absent in younger cases. The level of TauDeltaCsp6-positive NFTs and NPTs correlates inversely with global cognitive scores in NCI individuals. Therefore, Csp6 activity can occur with aging in the absence of AD and is always associated with clinical and pathological features of confirmed AD cases. Given the ability of active Csp6 to increase amyloid-beta peptide production and cleave Tau and several synaptic proteins (LeBlanc AC, Liu H, Goodyer C, Bergeron C, Hammond J: Caspase-6 role in apoptosis of human neurons, amyloidogenesis and Alzheimer's disease. J Biol Chem 1999, 274:23426-23436; Petzke TL, Rousselet E, Goodyer C, LeBlanc AC: Substrates of caspase-6 in human primary neurons: a proteomic study. Program No. 80.9. 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online), we suggest that active Csp6 could be an early instigator of neuronal dysfunction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392160      PMCID: PMC1829454          DOI: 10.2353/ajpath.2007.060974

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  28 in total

1.  Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment.

Authors:  J H Kordower; Y Chu; G T Stebbins; S T DeKosky; E J Cochran; D Bennett; E J Mufson
Journal:  Ann Neurol       Date:  2001-02       Impact factor: 10.422

2.  Clinical validity of Braak neuropathological staging in the oldest-old.

Authors:  G Gold; C Bouras; E Kövari; A Canuto; B G Glaría; A Malky; P R Hof; J P Michel; P Giannakopoulos
Journal:  Acta Neuropathol       Date:  2000-05       Impact factor: 17.088

3.  Mild cognitive impairment represents early-stage Alzheimer disease.

Authors:  J C Morris; M Storandt; J P Miller; D W McKeel; J L Price; E H Rubin; L Berg
Journal:  Arch Neurol       Date:  2001-03

4.  Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

Authors: 
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

5.  Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation.

Authors:  Sandrine Ruchaud; Nadia Korfali; Pascal Villa; Timothy J Kottke; Colin Dingwall; Scott H Kaufmann; William C Earnshaw
Journal:  EMBO J       Date:  2002-04-15       Impact factor: 11.598

6.  Neuropathology of cognitively normal elderly.

Authors:  D S Knopman; J E Parisi; A Salviati; M Floriach-Robert; B F Boeve; R J Ivnik; G E Smith; D W Dickson; K A Johnson; L E Petersen; W C McDonald; H Braak; R C Petersen
Journal:  J Neuropathol Exp Neurol       Date:  2003-11       Impact factor: 3.685

7.  Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease.

Authors:  Huishan Guo; Steffen Albrecht; Martine Bourdeau; Tracy Petzke; Catherine Bergeron; Andrea C LeBlanc
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

8.  Natural history of mild cognitive impairment in older persons.

Authors:  D A Bennett; R S Wilson; J A Schneider; D A Evans; L A Beckett; N T Aggarwal; L L Barnes; J H Fox; J Bach
Journal:  Neurology       Date:  2002-07-23       Impact factor: 9.910

9.  Caspase activation increases beta-amyloid generation independently of caspase cleavage of the beta-amyloid precursor protein (APP).

Authors:  Giuseppina Tesco; Young Ho Koh; Rudolph E Tanzi
Journal:  J Biol Chem       Date:  2003-09-05       Impact factor: 5.157

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  83 in total

1.  Identification of Caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimer's disease: a novel link to dysfunction in ubiquitin proteasome system-mediated protein degradation.

Authors:  Dalia Halawani; Sylvain Tessier; Dominique Anzellotti; David A Bennett; Martin Latterich; Andréa C LeBlanc
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

2.  Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.

Authors:  Juliette Gafni; Theodora Papanikolaou; Francesco Degiacomo; Jennifer Holcomb; Sylvia Chen; Liliana Menalled; Andrea Kudwa; Jon Fitzpatrick; Sam Miller; Sylvie Ramboz; Pasi I Tuunanen; Kimmo K Lehtimäki; X William Yang; Larry Park; Seung Kwak; David Howland; Hyunsun Park; Lisa M Ellerby
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

3.  Crystal structures of human caspase 6 reveal a new mechanism for intramolecular cleavage self-activation.

Authors:  Xiao-Jun Wang; Qin Cao; Xiang Liu; Kai-Tuo Wang; Wei Mi; Yan Zhang; Lan-Fen Li; Andrea C LeBlanc; Xiao-Dong Su
Journal:  EMBO Rep       Date:  2010-10-01       Impact factor: 8.807

Review 4.  Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease.

Authors:  Bruce A Yankner; Tao Lu
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

Review 5.  Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology.

Authors:  Bradley T Hyman; Junying Yuan
Journal:  Nat Rev Neurosci       Date:  2012-05-18       Impact factor: 34.870

6.  CASP3 and LDOC-1 gene expression in a patient with carcinoma in the hairy part of the head skin and Alzheimer disease.

Authors:  Michele Salemi; Pier Franco Soma; Paolo Bosco; Enzo Vicari; Roberto Castiglione; Castiglione Roberto; Aldo E Calogero
Journal:  Hum Cell       Date:  2013-06-18       Impact factor: 4.174

7.  Multiple proteolytic events in caspase-6 self-activation impact conformations of discrete structural regions.

Authors:  Kevin B Dagbay; Jeanne A Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-01       Impact factor: 11.205

Review 8.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

Review 9.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012

10.  Apoptosis and in vitro Alzheimer disease neuronal models.

Authors:  P Calissano; C Matrone; G Amadoro
Journal:  Commun Integr Biol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.